^
    Back
    Association details:
    Biomarker:MYC rearrangement + BCL2 rearrangement
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen: (carboplatin + carfilzomib + etoposide IV + ifosfamide + Rituxan (rituximab))
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ICML 2021
    Title:

    370 | A PHASE 1 STUDY OF CARFILZOMIB WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (C-RICE) IN TRANSPLANT-ELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

    Published date:
    06/09/2021
    Excerpt:
    MYC and BCL2/BCL6 rearrangements were noted in 3 pts, an additional 2 pts had an isolated MYC rearrangement. Best ORR was 62% (45% CR, 15% PR), 52% pts underwent HDC-ASCT....ORR of 100% was observed in pts with non-GCB DLBCL...C-RICE is well tolerated in pts with R/R DLBCL...